Moleculin Enterprise Value Trend from 2010 to 2022

MBRX
 Stock
  

USD 1.68  0.05  2.89%   

Moleculin Biotech Enterprise Value yearly trend continues to be fairly stable with very little volatility. Enterprise Value will likely drop to -22,527,237 in 2022. During the period from 2010 to 2022, Moleculin Biotech Enterprise Value regression line of anual values had slope of(2,196,250) and arithmetic mean of  16,987,135. Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.
  
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin main balance sheet or income statement drivers, such as Interest Expense of 39.7 K, Operating Expenses of 18.6 M or Research and Development Expense of 11.6 M, as well as many exotic indicators such as Total Assets Per Share of 3.74, Quick Ratio of 18.85 or Net Current Assets as percentage of Total Assets of 88.37. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules. It can also supplement various Moleculin Biotech Technical models . Additionally, see the analysis of Moleculin Biotech Correlation against competitors.

Moleculin Biotech Quarterly Enterprise Value

(19.97 Million)

Moleculin Enterprise Value Breakdown

Showing smoothed Enterprise Value of Moleculin Biotech CS with missing and latest data points interpolated. Enterprise Value (or EV) is usually referred to as Moleculin Biotech theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Moleculin Biotech debt, but would also pocket its cash. Enterprise Value is more accurate representation of Moleculin Biotech value than its market capitalization because it takes into account all of Moleculin Biotech CS existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.Moleculin Biotech's Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (17.68 M)10 Years Trend
Decreasing
Slightly volatile
   Enterprise Value   
Share
       Timeline  

Moleculin Enterprise Value Regression Statistics

Arithmetic Mean 16,987,135
Geometric Mean 23,445,062
Coefficient Of Variation 106.41
Mean Deviation 12,069,404
Median 21,598,847
Standard Deviation 18,076,279
Range 59,712,741
R-Value(0.47)
R-Squared 0.22
Significance 0.10
Slope(2,196,250)

Moleculin Enterprise Value History

201730.6 M
201819.6 M
201926.7 M
202037.2 M
2021-21.9 M
2022-22.5 M

Other Fundumenentals of Moleculin Biotech

About Moleculin Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moleculin Biotech income statement, its balance sheet, and the statement of cash flows. Moleculin Biotech investors use historical funamental indicators, such as Moleculin Biotech's Enterprise Value, to determine how well the company is positioned to perform in the future. Although Moleculin Biotech investors may use each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moleculin Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Enterprise Value over EBIT 1.00  1.08 
Enterprise Value over EBITDA 1.40  1.50 
Enterprise Value-21.9 M-22.5 M
Tangible Asset Value72.9 M78.7 M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moleculin Biotech Correlation against competitors. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
48 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.